Reduced sensitivity to beta-adrenoceptor stimulation and blockade in insulin dependent diabetic patients with hypoglycaemia unawareness.
Nine IDDM-patients with hypoglycaemia unawareness, seven IDDM-patients with hypoglycemia awareness and a control group of nine healthy persons were included in this study. The patients were recruited from the medical out-patients' department of the University Hospital of Tromsø. The pathophysiological changes which cause hypoglycaemia unawareness are today not clear. Reduced peripheral tissue sensitivity to catecholamines is suggested as one of several mechanisms which may contribute. For further investigation of beta-adrenergic sensitivity an isoprenaline/metoprolol sensitivity test was performed. Isoprenaline and metoprolol were administered intravenously, and the effects on heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP) and plasma levels of adrenaline (ADR) and noradrenaline (NA) were measured. All subjects were given the same doses of isoprenaline (0.25-8 micrograms) and metoprolol (0.5-8 mg). Metoprolol was given together with the dose of isoprenaline which increased heart rate by 25 beats min-1. The dose/response curves of both isoprenaline/HR and metoprolol/HR were significantly shifted to the right in IDDM-patients with hypoglycaemia unawareness compared with controls and IDDM-patients with hypoglycaemia awareness (P < 0.05). Reduced sensitivity of isoprenaline stimulation has also been shown before, whereas reduced sensitivity of a blocking agent has not earlier been shown. These findings support the hypothesis of reduced beta-adrenergic sensitivity as one pathophysiological component in hypoglycaemia unawareness.
Trovik
T S
TS
Department of Pharmacology, University of Tromsø, Norway.
Jaeger
R
R
Jorde
R
R
Sager
G
G
D000328:Adult; D000704:Analysis of Variance; D001364:Awareness; D001786:Blood Glucose / Q000032:analysis / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D002851:Chromatography, High Pressure Liquid; D003922:Diabetes Mellitus, Type 1 / Q000503:physiopathology*; D004305:Dose-Response Relationship, Drug; D004837:Epinephrine / Q000097:blood; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007003:Hypoglycemia / Q000503:physiopathology*; D007275:Injections, Intravenous; D007545:Isoproterenol / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D008297:Male; D008790:Metoprolol / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D009638:Norepinephrine / Q000097:blood; D011943:Receptors, Adrenergic, beta / Q000187:drug effects*; D012044:Regression Analysis
D001786:Blood Glucose; D006454:Hemoglobins; D011943:Receptors, Adrenergic, beta; D008790:Metoprolol; D007545:Isoproterenol; D009638:Norepinephrine; D004837:Epinephrine